Ben Isaacson - Scotiabank GBM
Analyst · Scotiabank. Your line is open
Hi, thank you. I was hoping just to get a bit of an update on MicroEssentials and specifically, can you just talk about how the economics are doing versus DAP, number one. Number two, what is the growth strategy for MicroEssentials beyond Brazil and North America? And then finally, just talk a little bit about your patents and when do those expire and how do you manage that? Thank you.
James T. Prokopanko - President, Chief Executive Officer & Director: Hey, good day, Ben. I'm going to turn it over to Rick McLellan in a minute to talk about how we're doing economically, but just wonderful that you asked question about the patent infringement case. Perhaps our GC who's in the room with us today, could add some color, but we got some very positive news last week, that most of the claims, virtually all of the claims have been thrown out by the court reviewing the matter. So, as far as we're concerned, we are in the clear on the patent infringement issue that was before us. So, do you want to say anything to that Mark – Mark Isaacson, our GC?
Mark J. Isaacson - Secretary, Vice President & General Counsel: Sure. Thanks Jim. Yeah, I would just add that the litigation that we're involved in, the federal litigation is – has been on hold for a number of years while the plaintiff's patent claims have been reviewed at the Patent and Trademark Office. And as it stands right now, most of those claims are back for review at the Patent and Trademark Office and have been held to be invalid by – at this latest review. And so again, I think we'll continue the litigation hold at this point and though the rest of it remains to be seen, but we think we're in a very good shape at this point.
James T. Prokopanko - President, Chief Executive Officer & Director: Okay, Rick, why don't you talk about the economics. I'm going to have Joc just speak to the production expansion after Rick addresses the economics of MEs (38:20).